-
Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year
-Data recently presented on FIRMAGON® (degarelix) hormonal therapy for prostate cancer showed that long-term use beyond one year…
-
Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.
-Ferring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™…
PRESS RELEASE 2010
PRESS RELEASE 2010